Semanteon Capital Management LP Acquires Shares of 9,097 Guardant Health, Inc. $GH

Semanteon Capital Management LP bought a new stake in Guardant Health, Inc. (NASDAQ:GH) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,097 shares of the company’s stock, valued at approximately $568,000.

A number of other large investors have also recently made changes to their positions in GH. TD Waterhouse Canada Inc. grew its holdings in Guardant Health by 3.2% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company’s stock valued at $306,000 after purchasing an additional 151 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Guardant Health by 8.3% during the third quarter. PNC Financial Services Group Inc. now owns 4,016 shares of the company’s stock valued at $251,000 after buying an additional 307 shares during the last quarter. Main Management ETF Advisors LLC raised its holdings in shares of Guardant Health by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 21,257 shares of the company’s stock worth $1,106,000 after buying an additional 348 shares during the period. CWM LLC boosted its holdings in Guardant Health by 21.6% during the 3rd quarter. CWM LLC now owns 2,020 shares of the company’s stock valued at $126,000 after acquiring an additional 359 shares during the period. Finally, F m Investments LLC grew its position in Guardant Health by 1.2% in the 2nd quarter. F m Investments LLC now owns 39,099 shares of the company’s stock valued at $2,035,000 after acquiring an additional 471 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Analysts Set New Price Targets

Several research firms recently commented on GH. Morgan Stanley raised their price target on shares of Guardant Health from $105.00 to $130.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Stifel Nicolaus raised their price objective on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Thursday, January 22nd. Evercore set a $110.00 price target on Guardant Health in a research report on Friday. Finally, Mizuho set a $135.00 price target on Guardant Health in a research note on Friday, January 9th. Twenty-one equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Guardant Health currently has a consensus rating of “Moderate Buy” and an average target price of $117.43.

Insider Transactions at Guardant Health

In related news, CFO Michael Brian Bell sold 80,362 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $103.14, for a total transaction of $8,288,536.68. Following the completion of the transaction, the chief financial officer owned 28,052 shares in the company, valued at $2,893,283.28. The trade was a 74.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Helmy Eltoukhy sold 90,565 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $103.82, for a total value of $9,402,458.30. Following the completion of the sale, the chief executive officer owned 2,047,143 shares of the company’s stock, valued at approximately $212,534,386.26. This trade represents a 4.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 434,511 shares of company stock worth $45,580,887. 6.10% of the stock is owned by corporate insiders.

Guardant Health Trading Down 3.1%

Shares of NASDAQ GH opened at $103.10 on Friday. Guardant Health, Inc. has a 12-month low of $34.88 and a 12-month high of $120.74. The stock’s fifty day simple moving average is $106.69 and its two-hundred day simple moving average is $86.22. The stock has a market capitalization of $12.99 billion, a PE ratio of -31.15 and a beta of 1.63.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The company had revenue of $281.27 million during the quarter, compared to analysts’ expectations of $269.74 million. During the same period in the prior year, the business earned ($0.62) EPS. Guardant Health’s revenue was up 39.4% compared to the same quarter last year. On average, equities analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.